PTC Therapeutics: One Of The Leaders In The Treatment Of Rare Diseases

Nathan Aisenstadt profile picture
Nathan Aisenstadt
2.83K Followers

Summary

  • PTC Therapeutics has been cooperating with Roche since 2011.
  • Evrysdi's sales were CHF 206 million in the fourth quarter of 2021, up 338% from the fourth quarter of 2020.
  • PTC Therapeutics management expects the company's revenue of $700-750 million in 2022, which is 34.6% more than in 2021.
  • The company has five approved medicines aimed at treating genetic diseases.

Крем осведомленности ленты в руке врача поддержки символический цвет лука для дегенеративных заболеваний диска (<a href='https://seekingalpha.com/symbol/DDD' title='3D Systems Corporation'>DDD</a>), паралич, травмы спинно

Chinnapong/iStock via Getty Images

PTC Therapeutics (NASDAQ:PTCT) is a global biopharmaceutical company that is one of the leaders in the treatment of Duchenne muscular dystrophy and SMA. The company has many approved drugs, and the best-selling of them are Translarna, Tegsedi, and Evrysdi, which

PTC Therapeutics Revenue

Author's elaboration, based on Seeking Alpha

PTC Therapeutics Revenue trend

Source: Author's elaboration, based on 10-K reports

PTC Therapeutics - Enduring innovation drives value creation

PTCT Corporate Presentation

PTC Therapeutics Evrysdi sales

Source: Author's elaboration, based on quarterly securities reports

Evrysdi net sales

Source: Author's elaboration, based on quarterly securities report

PTC Therapeutics Evrysdi

Source: Author's elaboration, based on quarterly securities report

Spinraza, Evrysdi, and Zolgensma

Source: Created by author

Sales of SMA drugs

Source: Created by author

Evrysdi approval

Source: Created by author

Roche and Genentech

Roche and Genentech

Roche and Genentech

Roche and Genentech

Roche and Genentech

Roche and Genentech

Evrysdi sales forecast

Source: Created by author

PTC Therapeutics product pipeline

PTCT Corporate Presentation

PTC Therapeutics PTC923

PTCT Corporate Presentation

PTC Therapeutics PTC923

Source: Created by author

Kuvan and Palynziq

Source: Created by author

PTC Therapeutics has a negative cash flow

Source: Author's elaboration, based on 10-K

PTC Therapeutics has a negative cash flow

Source: Author's elaboration, based on 10-K

PTC Therapeutics shares outstanding

Source: Created by author

PTC Therapeutics R&D

Source: Author's elaboration, based on 10-K

PTCT stock assumptions

Source: Created by author

PTCT stock average value

Source: Author's elaboration, based on Yahoo Finance

PTC Therapeutics financials

Source: Created by author

PTCT stock price target

Source: Created by author

This article was written by

Nathan Aisenstadt profile picture
2.83K Followers
I am an independent research analyst focused on finding undervalued assets with above-average growth rates and developments that can dramatically improve the company's financial position. When investing, I use medium-term and long-term trading strategies that take into account psychological and behavioral variables and are able to mitigate the risks associated with macroeconomic and geopolitical instability.The main sectors of analysis are industrials, materials, crypto, and healthcare.When analyzing assets in the healthcare sector, in addition to examining their financial position, I delve into the safety and efficacy data of the company's product candidates from preclinical and clinical studies, allowing me to evaluate their commercial prospects. While the education received at the Hebrew University of Jerusalem contributes to a comprehensive and detailed analysis of biotechnological and physicochemical processes used in the production of goods in the agricultural, oil and gas, and chemical industries. As a result, it allows me to find the most promising assets in a rapidly changing market and publish meaningful articles on Seeking Alpha.My e-mail for any questions and suggestions: aisenathan@gmail.com

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: This article may not take into account all the risks and catalysts for the stocks described in it. Any part of this analytical article is provided for informational purposes only, does not constitute an individual investment recommendation, investment idea, advice, offer to buy or sell securities, or other financial instruments. The completeness and accuracy of the information in the analytical article are not guaranteed. If any fundamental criteria or events change in the future, I do not assume any obligation to update this article.

Recommended For You

Comments (16)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.